A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to to determine the recommended dose level of JNJ-30979754
(decitabine) as well as to assess the safety and effectiveness in patients with
Myelodysplastic Syndrome (MDS).